Investigation of the Use of a Probiotic Supplement in People With Long COVID

Launched by SHEFFIELD HALLAM UNIVERSITY · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether a probiotic supplement can help improve symptoms in people suffering from Long COVID. Long COVID refers to ongoing health issues that some individuals experience for at least 12 weeks after having COVID-19. The study is currently looking for participants aged 65 to 74 years who fit the criteria for Long COVID, meaning they have persistent symptoms after their COVID-19 infection. However, individuals with serious health conditions, such as heart disease or cancer, will not be eligible to join.

If you decide to participate, you will be part of a double-blinded randomized trial, meaning neither you nor the researchers will know who is receiving the probiotic and who is receiving a placebo (a non-active treatment). This approach helps ensure that the results are fair and reliable. Participants can expect regular check-ins and assessments to monitor any changes in their symptoms throughout the study. Overall, this trial aims to determine if probiotics can provide relief for those experiencing the lingering effects of COVID-19.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: Long COVID defined as National Institute for Health and Care Excellence (NICE) criteria for Long COVID (Persistent symptoms at least 12 weeks after a confirmed or suspected Covid-19 infection).
• • -
• • Exclusion Criteria: Significant co-morbidities - no pre-existing diagnosis of hypertension, diabetes, cerebrovascular, cardiovascular or peripheral vascular disease, coagulopathy or haematological disorder or current or recent cancer.
• • -